SureTrader
Home > Boards > US OTC > Medical - Equipment >

Calmare Therapeutics Inc. (CTTC)

CTTC RSS Feed
Add CTTC Price Alert      Hide Sticky   Hide Intro
Moderator: conix, dr_lowenstein, mog1962
Search This Board: 
Last Post: 4/15/2018 9:05:49 PM - Followers: 39 - Board type: Free - Posts Today: 0

 

                                                                      

Calmare Therapuetics Incorporated.,  (OTCQX: CTTC)


MAYO CLINIC News on Calmare (November, 2014) 
http://www.reuters.com/video/2014/09/30/scrambling-away-pain-for-cancer-patients?videoId=346379225&videoChannel=6  
 

   
 
  



 ________________________________________________________________________________________________________________________________

 

Only machine of its kind in SC appears to get results for patients in pain

Helen Adams | adamshel@musc.edu | May 18, 2017

 

Retired teacher Douglas Foxworth was suffering from pain so severe that it felt like his feet were on fire. The cause was unknown — it’s called idiopathic peripheral neuropathy. When the Sumter man heard about a new pain treatment at MUSC Health called scrambler therapy, he jumped at the chance to try it.

“That morning when I went in, I was practically in tears. When they asked how my pain was, I said a nine, pushing a ‘ten’ out of ten,” Foxworth said.

He became one of the first patients in South Carolina to try scrambler therapy. The scrambler device, by Calmare, has been cleared by the Food and Drug Administration. Nurse Julie Watson described how it works. “The scrambler therapy device uses transcutaneous electrical stimulation to replace maladaptive pain information with ‘non-painful’ or ‘normal’ messages. It does this by traveling along the same pathways to the brain.” 

In other words, as its name suggests, scrambler uses electrical stimulation on the skin to scramble what nerves are trying to tell the brain. Each treatment lasts between a half-hour and 45 minutes. Foxworth had 12 sessions over a 2 1/2-week period. “The first day when they put those electrodes on, about 10 or 15 minutes after, the pain level went down,” he said. “It didn’t last, but the pain level went down to where it was tolerable.”

By the end of the 12th session, the difference was dramatic. “I still have some pain, but I’m no longer on pain medication. The pain is very mild,” Foxworth said. “I consider that this was effective to eliminate probably 90 percent of my pain.”

Palliative care specialist Pat Coyne, who introduced scrambler therapy at MUSC Health, said about 80 percent of the patients who try it feel a substantial difference. He first heard about scrambler therapy while he was working at Virginia Commonwealth University. “We did three research studies,” he said. “We went into the research trying to prove it didn’t work, and everyone kept saying they felt better.”

The skepticism Coyne initially felt resonates with MUSC Health palliative care doctor John Gibson. “Our team has been very happy with the results we have seen,” Gibson said. “I think the biggest point of skepticism for everyone who sees scrambler is that no one really understands how it works. There are theories that make sense, but no one has proven how it works.”

Scrambler therapy was invented by an Italian professor, Coyne said. It has been around for almost two decades, but wasn’t introduced in the U.S. until around 2010. The device requires careful monitoring. “With the electrodes, it senses the nerve firing. The electricity comes in wave forms and pulses. You adjust those based on when the patient tells you the pain is going away,” Coyne said. 

His research team wasn’t alone in finding scrambler therapy was effective. An article in the journal Supportive Care in Cancer said 19 out of 20 reports on scrambler therapy came up with positive results.

It’s a nuanced treatment, Coyne said. “A nurse is going to be sitting at the bedside and adjusting the dials. It will be different each time, and the leads will change because the pain typically gets smaller with each treatment. Really, what it’s trying to do is, when the nerves fire, it’s firing against them. So the pulsation never makes it to the brain and you don’t feel pain. And in doing so, we know it changes the way calcium is absorbed. Nerves that fire a lot actually are sometimes calcium deprived. You’re trying to reset the nerves to normal.”

Coyne said research shows patients who had scrambler therapy showed improvements in their natural pain-fighting reserves. “They get depleted when they’re fighting pain all the time. We found their endorphins changed.”

During a training period at MUSC Health, patients could volunteer to try scrambler therapy. It’s now in use in MUSC Hollings Cancer Center, covered by Medicare, Medicaid, and some insurance providers. “Starting off, we’re going to focus on the cancer population, but it’s going to be open to anyone who has this nerve pain,” Coyne said.

Watson, who has treated patients with the scrambler, said cancer treatments can cause neuropathic pain and sensation problems. “They may be able to stay on their treatments longer or at doses they may not have been able to previously tolerate. This treatment can be life-changing for some by enhancing quality of life and allowing them to do activities they may not have previously been able to do,” Watson said. 

“We treated a patient with chemo-induced neuropathy, and he wanted to work out and jump rope as he once did. Before he completed his treatments, his numbness had improved so much in his feet that he began jumping rope, which he had not been able to do for several years. Having a non-invasive, non-pharmacological alternative such as scrambler therapy that has shown proven benefit for neuropathic pain is a tremendous stride here at MUSC Health.”

Gibson, the palliative care physician, said it’s important to look for new ways of treating pain. “Unfortunately, and despite years of effort, the health system does not do a great job of treating pain, particularly neuropathic pain, which is really what scrambler is targeted toward,” he said.

“The mainstay of treatment currently is drugs, all of which come with a number of side effects. In many instances, these medicines do not adequately control the pain or cannot be tolerated by the patient. Among these medications are the opioids, which pose possible risks to the patient, and as everyone now has seen commonly on the news, opioids come with a heavy burden on our public health," Gibson said.

Neuropathic pain, particularly chemotherapy-induced neuropathy, is typically a chronic form of pain. "There is very little evidence that opioids are effective in chronic pain, and there are significant issues with tolerance to these medicines which often leads patients to higher and higher doses of the medicine, usually with more side effects," Gibson said. "Scrambler offers the potential to significantly reduce the patient’s pain with basically no side effects and no ongoing need to take pills. Without the pills, many of the societal burdens of pain medicines will be reduced as well.”

Coyne envisions having several scrambler devices at MUSC Health in the future. With scrambler therapy, he said, “The numbness goes away, which no one’s ever found a way to fix. Some meds take away the pain, but the numbness stays.”

To be treated with scrambler therapy at MUSC Health, patients must have a referral from a doctor. Watson said common conditions treated include chemo-induced neuropathy, diabetic neuropathy, phantom limb pain, failed back syndrome, trigeminal neuralgia, postherpetic neuralgia and chronic regional pain syndrome.

Before scrambler therapy, Foxworth, the teacher from Sumter, was taking the pain reliever gabapentin. He’s not anymore, but knows his pain may flare up again. “More than likely it will reoccur. When that happens, I’ll go back for what they call a booster treatment. I’m very pleased with what scrambler therapy has done for me."

http://academicdepartments.musc.edu/newscenter/2017/scrambler/index.html]b\[

-----------------------------------------------------------------------------------------
 

Berkeley, California Neurology Practice Adds Calmare(R) Pain Management Therapy

Dr. Selena Ellis to Treat Chronic Neuropathic Pain with Non-Invasive and Non-Addictive Technology

BERKELEY, CA - (NewMediaWire) - June 13, 2017 - Dr. Selena Ellis (www.selenaellismd.com) is proud to announce her medical practice will be the first neurology practice in the western United States to offer Calmare® therapy, an effective non-opioid treatment for neuropathic pain. Dr. Ellis's medical practice treats chronic pain in patients suffering from trigeminal neuralgia, peripheral neuropathy, complex regional pain syndrome (CRPS), headaches and migraines. After an in-depth evaluation process which included the successful treatment of her patients with chronic neuropathic pain, Dr. Ellis has recently added this very promising therapy, also known as "Scrambler Therapy".https://www.foundationforpn.org/2016/12/09/scrambler-therapy-for-treating-neuropathic-pain/)

Calmare® is a FDA-cleared device that provides a non-invasive therapy for the treatment of chronic neuropathic pain. Calmare® therapy has also been successful in achieving chronic pain relief for patients suffering from failed surgical back syndrome and multiple neuropathies including chemotherapy-induced peripheral neuropathy (CIPN). http://www.reuters.com/video/2014/09/30/scrambling-away-pain-for-cancer-patients?videoId=346379225&videoChannel=6.

Significantly, there have been no reports of adverse side effects associated with this therapeutic modality.

The Calmare® technology employs electrostimulation with a low electrical current directed at the central nervous system and delivered through applied electrodes on the patient's skin surrounding the pain area. Sixteen electrical impulse algorithms are programmed to specifically target the body's sensory fiber pathway (which transmits slower and chronic pain signals). These electrical signals help "re-program" the brain's receipt of the pain signal. In many patients, these signals provide longer-lasting pain relief than those that "blocking" the pain signal, such as with transcutaneous electrical nerve stimulation (TENS).

Treatment

Physicians using Calmare therapy have reported that patients who experience a reduction in pain after their first 45-minute treatment have a high probability of experiencing a significant reduction in chronic pain after completing a ten-treatment regimen. Patients should be weaned off certain medications before starting the therapy to achieve the best result.

Dr. Ellis says, "My practice focuses on providing chronic pain relief to my patients using the most safe, effective and non-addictive therapies available. As a neurologist, I am open to new modalities after conducting a complete evaluation of the patient. After I saw the positive results in some of my patients after using Calmare, I knew I wanted to be the first neurologist to offer the technology in the western US."

About Selena Ellis, MD (www.selenaellismd.com)

Dr. Ellis attended medical school at the University of Washington in Seattle and completed her neurology residency at the UCLA School of Medicine in 2002. She obtained subspecialty training in electrodiagnosis of neuromuscular disease as Chief Resident and Fellow at the Wadsworth VA/UCLA Department of Neurology.

Dr. Ellis is board-certified in general neurology and electrodiagnostic medicine by the American Board of Psychiatry and Neurology (ABPN) and the American Board of Electrodiagnostic Medicine (AANEM). She was the president and longtime board member of the San Francisco Neurological Society http://www.sfneurological.org/board.html. Dr. Ellis had the first medical practice in Northern California with an AANEM-certified electromyogram (EMG) lab, in addition to being the first neurologist in the western US to offer Calmare therapy.

Dr. Ellis treats common neurological disorders such as headache, peripheral neuropathy, trigeminal neuralgia, occipital neuralgia, complex regional pain syndrome, back pain, and sciatica. Other common symptoms treated at her practice include pain syndromes of many types, difficulty with gait or balance, and sensory changes to the arms or legs. Dr. Ellis also has subspecialty training in evaluation and management of problems affecting the peripheral nervous system, including systemic neuropathies, mononeuropathy and radiculopathy.

About Calmare/Scrambler Therapy

Distributed by Competitive Technologies, Inc., the Calmare® (also known as Scrambler therapy) is a U.S. FDA 510(k)-cleared and European CE mark-certified pain therapy medical device for the non-invasive and non-narcotic treatment of chronic neuropathic and oncologic pain. Using a biophysical rather than a biochemical approach, Calmare employs a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin surrounding the area in pain. The device creates and relays a non-pain signal which becomes the dominant signal received by the brain and overrides the pain signal to provide relief for the patient. The Calmare device has been used to successfully treat over 10,000 chronic pain patients worldwide. 

Contact:

Cynthia Laird at 510-644-2282 for Dr. Selena Ellis or
officemanager@selenaellismd.com

http://www.newmediawire.com/news/berkeley-california-neurology-practice-adds-calmare-r-pain-management-therapy-4818055


--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SureTrader
CTTC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
CTTC News: Statement of Changes in Beneficial Ownership (4) 03/06/2018 01:12:15 PM
CTTC News: Statement of Changes in Beneficial Ownership (4) 03/06/2018 01:10:52 PM
CTTC News: Statement of Changes in Beneficial Ownership (4) 03/06/2018 01:09:51 PM
CTTC News: Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) 02/20/2018 09:47:57 AM
CTTC News: Current Report Filing (8-k) 02/20/2018 06:33:20 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#14859   News this week!!! andy55q 04/15/18 09:05:49 PM
#14858   What new management? Indeed, did current managements parkourstar 04/12/18 09:10:26 PM
#14857   Any update on the new manageream?? andy55q 04/12/18 07:41:55 AM
#14856   This is only the beginning: powderbum 04/12/18 01:29:05 AM
#14855   On a positive note, consider that Calmare shares, mog1962 04/06/18 11:28:16 AM
#14854   Where’s Stan Stan the Money Man!! andy55q 04/05/18 01:55:10 PM
#14853   and where, if it was payable, would they mog1962 04/05/18 11:55:57 AM
#14852   NEWS!--Conrad Mir, CEO of CTTC, Announces $12 Million conix 04/05/18 11:15:40 AM
#14851   No Sales, No News , No Nothing!!! andy55q 04/03/18 07:00:10 AM
#14850   Yeah, well, Stan would have a lot more parkourstar 04/02/18 05:43:50 PM
#14849   Mog You've made some fair points. I feel the powderbum 03/31/18 09:48:14 AM
#14848   If all that you say is true, then Onya 03/30/18 06:16:10 AM
#14847   conix I think the overall problem is that a mog1962 03/29/18 02:09:02 PM
#14846   How is "Dr." Marineo doing these days, conix 03/29/18 12:18:59 PM
#14845   The issues and questions are about: mog1962 03/29/18 11:54:48 AM
#14844   There is no issue who made them. They powderbum 03/29/18 10:43:26 AM
#14843   Ok sure, but who made the Scrambler andy55q 03/29/18 08:26:42 AM
#14842   Units approved for manufacturing under their 510-K, They powderbum 03/29/18 07:27:43 AM
#14841   CTTC is out of business also!! andy55q 03/28/18 10:08:11 PM
#14840   When was the last time GEOMC manufactured MC powderbum 03/28/18 07:19:22 AM
#14839   Apart from this information publicly available & more Onya 03/28/18 06:30:22 AM
#14838   When was the last time GEOMC manufactured MC powderbum 03/27/18 06:08:53 PM
#14837   So they manufacturer their own device. who is Onya 03/27/18 04:43:19 PM
#14836   We all now know who's shill you are.How powderbum 03/27/18 11:13:01 AM
#14835   Do your research! Two very different devices. Onya 03/27/18 06:59:33 AM
#14834   I guess you were wrong! powderbum 03/26/18 06:18:59 PM
#14833   A little humor for the day: parkourstar 03/26/18 11:45:10 AM
#14832   A better question might be who gives a parkourstar 03/26/18 11:21:36 AM
#14831   "Could it be these trial are the new powderbum 03/26/18 09:59:02 AM
#14830   No I don't and I don't want to Munchqin 03/25/18 09:15:29 PM
#14829   Do you know Dr. Smith, Munchqin? Have conix 03/25/18 08:12:02 PM
#14828   "the results of these studies are NOT publishable Munchqin 03/25/18 05:25:08 PM
#14827   http://urhealthguide.com/neurontin-lyrica-death-sentence-new-brain-synapses-shoc powderbum 03/25/18 10:12:26 AM
#14826   With all due respect, IMHO, the results of Bigspirit1 03/25/18 09:03:15 AM
#14825   "birds of a feather flock together" Conrad and Munchqin 03/24/18 10:38:22 PM
#14824   Stop...I meant (not Sop) .. a typo, Sorry! Munchqin 03/24/18 10:27:38 PM
#14823   Sop the sympathy to Smith, he is an Munchqin 03/24/18 10:26:12 PM
#14822   I told you this. Check my prior replies Munchqin 03/24/18 10:20:06 PM
#14821   Sadly, Onya is probably right on with his mog1962 03/24/18 07:45:24 PM
#14820   Good questions that needs to be answered!! andy55q 03/24/18 07:11:31 PM
#14819   Scrambler therapy trials......not calmare therapy?? Onya 03/24/18 06:05:07 PM
#14818   Interesting to me that Dr. Smith finished this powderbum 03/24/18 02:52:09 PM
#14817   VA has been paying for Calmare to private doctors. powderbum 03/20/18 11:17:22 AM
#14816   In-the-mean-time. There are huge opportunities in this industry powderbum 03/19/18 09:29:16 AM
#14815   Personally, I am hoping that Brennan, Mir and conix 03/19/18 12:24:56 AM
#14814   Powderbum The questions are: mog1962 03/17/18 03:08:06 PM
#14813   10 years of bad management. Time for a change! powderbum 03/17/18 11:55:40 AM
#14812   10 Years and still not FDA approved !! andy55q 03/15/18 08:15:37 PM
#14811   Still do not have FDA approval!!! andy55q 03/15/18 07:46:19 PM
#14810   This illegal manipulation of the cap structure to conix 03/15/18 10:51:49 AM
PostSubject